Who is sponsoring NCT00619892?

NCT00619892 is sponsored by Indiana University.

What condition does NCT00619892 study?

NCT00619892 studies Panic Disorder.

What drugs are being tested in NCT00619892?

Interventions: quetiapine XR, placebo.

What is the status of NCT00619892?

NCT00619892 is currently COMPLETED.

Last reviewed 2015-12-15 · How we verify

An 8-week, Randomized, Double-Blind, Placebo-Controlled Trial of Seroquel SR Co-administration for SSRI-Resistant, Comorbid Panic Disorder

NCT00619892 Phase 4 COMPLETED Results posted

The primary objective of this study is to test the hypothesis that a SSRI plus quetiapine SR (Seroquel SR) will result in superior early (first 1-3 weeks of treatment) stabilization of panic symptoms in SSRI-resistant, comorbid Panic Disorder patients versus a SSRI plus placebo.

Details

Lead sponsor	Indiana University
Phase	Phase 4
Status	COMPLETED
Enrolment	26
Start date	2008-02
Completion	2011-12

Conditions

Panic Disorder

Interventions

quetiapine XR
placebo

Primary outcomes

Change in Mean Total Panic Disorder Severity Scale (PDSS) Scores — Baseline and the end of 8 weeks of treatment
Possible total scores on the PDSS range from 0-28. The outcome measure represents the change, between baseline and the end of 8 weeks of treatment, in the the total PDSS scores. Lower scores indicate less severe panic disorder symptoms. A negative mean change in the scores at the end of 8 weeks represents a decrease in severity of panic disorder symptoms.

Countries

United States